Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bacteria-mediated cancer therapy is a potential therapeutic strategy for cancer that has unique properties, including broad tumor-targeting ability, various administration routes, the flexibility of delivery, and facilitating the host's immune responses. The molecular imaging of bacteria-mediated cancer therapy allows the therapeutically injected bacteria to be visualized and confirms the accurate delivery of the therapeutic bacteria to the target lesion. Several hurdles make bacteria-specific imaging challenging, including the need to discriminate therapeutic bacterial infection from inflammation or other pathologic lesions. To realize the full potential of bacteria-specific imaging, it is necessary to develop bacteria-specific targets that can be associated with an imaging assay. This review describes the current status of bacterial imaging techniques together with the advantages and disadvantages of several imaging modalities. Also, we describe potential targets for bacterial-specific imaging and related applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.addr.2022.114366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineered Strains Colonization at Tumor Sites: A Novel Approach to the Delivery of Cancer Treatments.
Cancers (Basel)
July 2025
Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Bacteria-mediated cancer therapy represents a novel and promising strategy for targeted drug delivery to solid tumors. Multiple studies have demonstrated that various species can selectively colonize the hypoxic microenvironments characteristic of solid tumors. Leveraging this property, has been explored as a delivery vector for a range of anti-cancer approaches such as immunotherapy, nanoformulated chemotherapeutics, and gene therapy.
View Article and Find Full Text PDFTargeting Cancers with Microrobots and Bacteriobots.
Mol Biotechnol
August 2025
Department of Biochemistry, Central University of Punjab, VPO Ghudda, Punjab, 151401, India.
Developing efficient medication delivery systems is a key area of research that will improve the efficacy of cancer treatments. As cancer cells have certain characteristics, it is crucial to precisely deliver chemotherapeutic drugs to the tumor microenvironment without harming healthy tissues. There has been a growing interest in exploiting biological agents to overcome the disadvantages of traditional cancer treatments in targeting and delivering drugs.
View Article and Find Full Text PDFLiving therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy.
Nat Commun
July 2025
Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China.
Anaerobic bacteria-mediated tumor therapy faces multiple challenges, including potential toxic side effects, complex manufacturing processes, and impaired hypoxic targeting. Here, based on the excellent biocompatibility and distinctive metabolic ability of natural anaerobic sulfate-reducing bacteria (SRB) to dissimilate sulfate into sulfide, we construct in situ-biosynthesized ferrous sulfide nanoparticle-SRB (FeS@SRB) biohybrid to enhance tumor-targeted therapy. Interestingly, SRB acts as both a biosynthesis factory and active tumor-targeted delivery vehicles.
View Article and Find Full Text PDFOptimized bacterial delivery approaches for precision immunotherapy in breast cancer models.
J Control Release
September 2025
Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongup 56212, Republic of Korea; University of Science and Technology (UST), Daejeon 34113, Republic of Korea. Electronic address:
Bacteria-mediated cancer therapy is an innovative approach that exploits the tumor-targeting ability of bacteria to deliver anti-cancer drugs directly to tumors. Cytolysin A (ClyA), a bacterial pore-forming toxin, has demonstrated therapeutic efficacy in colorectal cancer but has limited effectiveness in breast cancer. To address this limitation, we engineered an attenuated Salmonella strain to express Clostridium perfringens enterotoxin (CPE), which selectively targets CLDN-4, a tight junction protein overexpressed in breast cancer, thereby minimizing off-target effects.
View Article and Find Full Text PDFEnhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis.
J Immunother Cancer
July 2025
Orthopedics, Ruijin Hospital, Shanghai, Shanghai, China
Background: Osteosarcoma (OS) with pulmonary metastasis remains challenging due to limited treatment options and the immunosuppressive nature of the tumor microenvironment (TME). Bacteria-mediated cancer therapy has emerged as a promising strategy for solid tumors but often suffers from limited efficacy due to the immunosuppressive TME, which restricts the intensity and durability of the antitumor immune response. To overcome these challenges, we engineered a novel Salmonella strain, VNP20009-CCL2-CXCL9 (VNP-C-C), leveraging the intrinsic tumor tropism of VNP20009 (VNP) and improving immune modulation through the recruitment of effector immune cells into the TME by the chemokines CCL2 and CXCL9.
View Article and Find Full Text PDF